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To help save lives and improve human health, it is crucial for policy
makers to ensure equity in access to drugs, drug efficacy, quality and safety,
and rational use of drugs, which are indicators of the National Drug Policy
(NDP) in evaluation of pharmaceutical system performance in every
country. There are some retrospective evaluation methods that are
currently used to appraise the success of NDP and adherence to its
objectives in the relevant countries.
Nikfar et al. (2005) for the first time designed a weighted questionnaire
system by a nominal group technique based on the answers to the
questions for adding a single drug to the National Drug List (NDL). They
found that although the system, structures, and mechanisms are in place,
they do not function properly in some topics. Assessment of 59 dossiers
of approved drugs for adding to the NDL during a 5-year period showed
that decision makers pay more attention to efficacy, safety, and rationality
in use rather than accessibility and affordability. Nikfar et al. (2005)
concluded that every country must establish a survey system to check
implementation of the processes to achieve the NDP's objectives of better
protection of public health and equal access to pharmaceuticals [1]. Our
belief is that the problem is still there and has not been resolved yet by
the national drug authority (NDA) and the objectives of national drug
policies (NDP) have not been met yet [2].
Adding or deleting medicines from the essential lists, establishing
national formularies, registering the health professionals, facilities and
goods, financial interventions, pricing and reimbursement, supervising the
supply chain, pharmacovigilance, regulating advertising, and promoting
rational drug use are some of the daily decisions that are made by NDAs.
On the other hand, some factors in the market such as product
specifications, prices, supply system and promotion affect the decisions.
Furthermore, the cost of drugs is a hurdle for utilization as despite
availability it affects accessibility [3-5]. 
These mixed variables complicate decisions that are needed to be made
even in uncertain conditions. The  NDAs usually cannot predict and
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evaluate consequences of their decisions. Although
some national and international organizations offer
some key indicators for evaluation of NDP on the
basis of availability, affordability, quality, and
rationality, these indicators are often retrospective
and they need time-consuming data collecting
procedures.
Lack of key indicators for evaluation of NDP in
many countries causes failure in determining the
relationship between health indices and the volume
of the pharmaceutical market [2]. Although these
countries have organizations and rules for
regulating medicines, the system often does not
function properly [6, 7]. Sometimes lack of tools for
predicting the future leads to some policies which
could not be evaluated at the time of decision
making [5]. In the case of safety, efficacy, and
quality, NDAs usually try to follow major
organizations such as the FDA or EMEA; but to
enhance availability and affordability, each country
needs its own local solutions. Accurate national
economic and health data, sufficient human
resources, clarified rules and efficient structure are
some prerequisites for calculation of the indicators
that are the main weaknesses of most countries.
Of course, the consequences of these defects would
be extended to the life of all people and the
community and health policy makers [8].
According to the mentioned explanations,
pharmaceutical policy makers need a kind of
decision support system which should be
responsible for the following tasks:
– shortening the decision process, 
– increasing the rationality of actions, 
– evaluating the different alternatives, 
– reducing the costs, 
– decreasing the human-derived mistakes, 
– increasing reliability and validity, 
– providing potentials for sensitivity analysis and
repeatability.
Recently, modelling and simulation techniques
have created an opportunity to reduce the costs
and risks of uncertain conditions. Searching
bibliography databases shows the techniques that
are used in artificial physician software and in the
quantitative structuring of drugs. In managerial
work and policy making, modelling and simulation
have been applied in some fields [9, 10]. 
Although there are a few articles about the use
of simulation models as a decision support system
for hospitals or disease management, we think that
developing a well-adjusted model is crucial to
reduce the risk of decisions in pharmaceutical
policy.
There are many models for simulation but only
a few of them have been used in the health care
system. They are as follows:
• Mathematic models that try to put all relations
and interactions between variables in a unique
formula. Deferential equations, Fourier-type series
and expansions are some methods in this
modelling. Validation of the model strongly relies
on the quantity and quality of variables which are
used in the model [11].
• Econometric models use statistical regression to
make an equation between independent and
dependent variables. Although there are many
techniques to adjust the best model to variables,
many unknown factors in pharmaceutical markets
decrease the accuracy of the model. In spite of
the accuracy of the models, regression models
connect some input variables to one output
variable. In this situation, we have many NDP
indicators as the output variable and some output
variables are inputs for other models. Thus we
need at least one regression model for each
output variable, which unfortunately would make
the model too complicated [12].
• Artificial neural networks simulate the neurons’
functions by connecting some input variables to
some output variables. These models have to be
trained to show an acceptable accuracy, but for
training they need too many data. Usually it 
is impossible to find a good data source for model
variables, especially in developing countries 
[12, 13].
• System dynamic is another model to simulate
many industrial, social and natural events. In
these models, complicated events break down to
simple parts, and then some stocks and flows are
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Figure 1. The expected model of support system to simulate national drug policies indicators
The expected model
• All inputs might affect outputs
• Some outputs might affect input
• Some other variables might
affect the model
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defined. Changes in flows and stocks levels can
simulate the events. These models can adjust
many social and managerial situations easily.
Usually mathematical equations define relations
between stocks [14, 15].
Here, to develop a decision support system to
simulate NDP indicators, we propose 3 main groups
of input variables and 4 main groups for output, as
shown in Figure 1.
The three main groups of input variables are:
1. Common variables such as population and its
structure, economics and health situation.
2. Disease variables including prevalence, incidence,
burden, duration and treatments.
3. Pharmaceutical market-related variables such as
product specification, price, supply chain,
promotion and people (4 Ps in marketing:
Product, Price, Place, and Promotion).
Output variables are NDP indicators including
availability, affordability, quality, and rationality
indices. The model is supposed to simulate the
interactions between input variables and predict
changes in output variables that should have some
specification:
1) It should be multi-variable to multi-variable,
having the capability to connect many inputs to
some output variables.
2) It doesn’t need so many data for training.
3) The model has to be as simplest as possible.
Based on the specifications and limitations of
mentioned models, a combination of the system
dynamics models and econometrics can simulate
the situations of the decision making process in
NDAs in the environment of the pharmaceutical
market and its variables. This simulation model
creates an opportunity to evaluate the
consequences of each decision in NDAs based on
NDP indicators. The model can be implemented in
software to help as a decision support system in
reduction of the risk of decision making in uncertain
situations.
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